UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Understand the dynamics of wealth building by comparing real estate and stocks. Find out which option may yield faster returns for your investments.
26,865 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
A new multi-asset crypto strategy fund has drawn record inflows, earning the label this year’s hottest crypto play as...
Markets react to kevin warsh’s first meeting as Fed chair, with stocks rising, bond yields fluctuating and traders we...
New York’s decision to pause large-scale data center projects up to a year changes the playing field for cloud giants...
A major fund recently disclosed a large move in Globalstar as the stock surged. This article explains what happened, ...
Nvidia delivered a blockbuster quarter, but the stock cooled off the next day. This article unpacks the mystery behin...
Critics have labeled this stock as overvalued for years, yet its price action and earnings trajectory tell a differen...
Investors buzzed as metals company stock rocketed higher on regulatory progress and strong demand signals for battery...
A growth stock down dip can open the door to meaningful long-term gains. Learn how to assess, plan, and act with conf...
SpaceX’s IPO buzz is reshaping how traders view tech hardware plays. This story explains why micron stock after space...
Tilray Brands is set to report on July 28. This article breaks down whether should tilray brands stock be on your rad...
Geopolitical headlines push risk-off moves while Hut 8 leads a tech rally on AI data center news. This guide breaks d...